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Abstract
Background: Pre-diabetes is a growing health concern where a large percentage of these patients develop full
type 2 diabetes. Effective interventions on pre-diabetes can prevent or delay the occurrence or development of
diabetes. Pharmaco-dynamics and pre-clinical of JinQi-Jiangtang tablets (JQJT) suggest that it could be benefit for
pre-diabetes.
Methods/Design: Randomized controlled trial (RCT) is implemented in this study. The study term is 24 months (12
months for intervention and 12 months for follow up). Participants are recruited from four cities of China: Beijing,
Tianjin, Xi’an and Nanning. Four hundred participants are randomized to treatment group (JQJT tablets) and
control group (Placebo); two hundred participants each. People being included in this study must have been
diagnosed as pre-diabetes via western medicine criteria and traditional Chinese medicine (TCM) criteria. The end-
point indexes include: incidence of diabetes mellitus and reversion rate. Primary outcome indexes include: oral
glucose tolerance test; insulin releasing test; glycosylated hemoglobin (HA1c). Secondary outcome indexes include:
score of the Short Form 36 Health Survey Questionnaire (SF-36); score of TCM symptoms; blood lipid test. Indexes
of safety include: general medical examination; blood and urine regular test; electrocardiogram (ECG), liver function
(ALT) and renal function (BUN, Creatinine) test; record of adverse event, such as headache, faint, etc. Qualitative
control will be implemented and a number of standard operating processes (SOPs) will be formed throughout the
study: laboratory quality control measures; compliance control for researchers and participants; researcher training
before study; supervision; investigational drug management and others.
Discussion: The aim of this study is to evaluate the effectiveness and safety of JinQi JiangTang (JQJT) tablets for
the treatment of patients with pre-diabetes.
Trial registration: Chinese clinical trials register ChiCTR-TRC-00000401
Background
An increasing number of people experience complica-
tions from symptoms of pre-diabetes. Some studies have
discovered that about 5%-10% of pre-diabetes will
develop into diabetes within one year and the occur-
rence of cardiovascular events in patients with pre-dia-
betes are higher than in healthy individual. According to
Hoorn[1], the rates of development of diabetes after 5.8-
6.5 years follow-up from patients with normal glucose
tolerance, single impaired fasting glucose (IFG), single
Impaired Glucose Tolerance (IGT), both IGT and IFG
people are 4.5%, 33.0%, 33.8% and 64.5%, respectively.
Therefore, the prevention of type 2 diabetes in pre-dia-
b e t i cp a t i e n t si sat o p i co f importance in diabetes
research.
Progress of pre-diabetes
Effective interventions on pre-diabetes can prevent or
delay the occurrence or development of diabetes; it can
also reduce micro-vascular and macro-vascular
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1986-1994 concluded that lifestyle interventions could
reduce the incidence of diabetes by 30%-50%[2]. How-
ever, another study confirmed that lifestyle interventions
were not completely effective to prevent the develop-
ment of type 2 diabetes for high-risk groups[3]. Another
study showed a high trend of body weight rebound and
blood glucose increase after 1-2 years of lifestyle inter-
ventions [4]. STOP-NIDDM discovered that IGT inter-
vention was able to reduce the occurrence of diabetes
by 36% [5]. DPP discovered that metformin and troglita-
zone can significantly reduce the risk of diabetes [6]. In
the TRIPOD study, troglitazone reduced the risk of dia-
betes by 55% in gestational diabetes patients [7]. The
latest DREAM trial showed that the intervention of pre-
diabetes can delay the disease process [8,9]. These stu-
dies give us hope to prevent diabetes effectively.
Prevention and treatment on pre-diabetes in traditional
Chinese medicine (TCM)
Traditional Chinese medicine (TCM) can treat pre-dia-
betes effectively[10]. A systematic evaluation of pre-dia-
betes intervention, including 19 randomized controlled
trials, showed that the combination of Chinese medicine
and lifestyle intervention can decrease fasting blood glu-
cose in 1471 cases. Meanwhile, the 2 hours postprandial
b l o o dg l u c o s ea n d2h o u r sp o s tprandial insulin levels
were lower than a simple lifestyle intervention [11].
Zhou Zhuoning[12]considered that diabetes can be
explained by three TCM Syndrome from IGT to dia-
betes as: yin deficiency with heat, dual deficiency of yin
and qi, dual deficiency of yin and yang in development.
Constituents of JQJT tablets
Alkaloid is the major constituent of Coptis, including
Berberine, palmatine, methyl and coptisine. Berberine is
the most content among them (accounting for 6.88%
~13.64%). The main chemical constituents of Astragalus
is flavonoids, saponins and polysaccharides. The main
chemical composition of Honeysuckle is volatile oils, fla-
vonoids, organic acids and other substances, chlorogenic
acids compound is the main active ingredient among
them. Berberine, flavonoidsc a nl o w e rb l o o ds u g a rs i g -
nificantly and chlorogenic acids compounds can
strengthen the immune system.
Pharmaco-dynamics of JinQi-Jiangtang(JQJT) tablets
￿ JinQi-Jiangtang (JQJT) tablets is composed by Cop-
tis, Astragalus, and Honeysuckle.
￿ Influence on glycometabolism: Studies before
proved that JQJT tablets can improve mice glucose
tolerance obviously[13]. Honeysuckle can decrease
blood sugar[14]. Berberine, as a natural plant
alkaloid isolated from the Coptis chinens, has been
noted for its potential glucose lowering effect[15].
￿ Influence on insulin resistance(IR) and serum insu-
lin: JQJT tablets can improve the insulin resistance
caused by Hydrocortisone and decrease the serum
insulin in mice[16].
￿ Influence on immune function: JQJT tablets can
improve immune function and protect thymus gland
atrophy of mice [16].
Pre-clinical of JQJT tablets
Sheng zhufang proved that JQJT tablets can improve
insulin resistance in humans[17]. Gu wenyuan indicated
that combination of JQJT tablets and Gliclazide can
improve fasting blood-glucose (FBG) of 2 type diabetes
patients[18]. Zhang rongrong discovered that JQJT
tablets can not only prevent the progression from pre-
diabetes to diabetes but also delay development of dia-
betic nephropathy (DN)[19].
Methods/Study design
Objectives
To evaluate the effectiveness and safety of JQJT tablets
for pre-diabetes in China by comparison with placebo.
Research type
Randomized controlled trial (RCT).
Screening of participants
400 pre-diabetes patients will be divided into the treat-
ment group and the control group (1:1). Participants
should be included according to diagnosis criteria and
inclusion criteria (reference to the next section).
Intervention
￿ Arrangement for intervention: All researchers in
this study will be trained before their participation.
Some measures will be implemented in order to
ensure compliance, such as compensation and prize.
Patient handouts will be delivered to every partici-
pants to instruct their medication and cooperation.
￿ Lifestyle intervention: Researchers will develop an
individual diet program for each participant, includ-
ing reasonable match of calories, protein and carbo-
hydrates, low-salt and low-sugar diet, advise them to
give up some bad diet habits. Risk factors, such as
smoking and alcoholics, will be controlled strictly.
Individual’s exercise program will be formulated for
all participants according to their age, gender, etc.
￿ Drug intervention: The period of drug intervention
is 12 months. All participants have to visit research-
ers every month. The interventions are as follows:
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each dose and twice daily, all the drugs are taken
before meal; Placebo of JQJT for control group, the
method and time of taking drugs is the same as
treatment group.
Randomization
The randomization of the trial will be completed by
the independent data center named Interact Voice
Responding System (IVRS). According to a random
sequence table (generated by SAS8.2), participants who
satisfied the inclusion criteria will be allocated ran-
domly into one of the two groups with a ratio of 1:1.
The identification code and random number, which is
unique for each participants, will be generated by the
IVRS.
Allocation concealment
All researchers will receive training of allocation con-
cealment at the central randomization office. The rando-
mization sequence schedule is held and controlled by
the appointed one who is not involved in this trials. The
schedule is secret for researchers, participants and other
research personnel before study, so allocation sequence
is implemented in a secure manner to prevent fore-
knowledge by either of them.
Blindness
Double-blinding method is adopted in this study. Simu-
lated agents of JQJT tablet have the same appearance,
shape, color and packaging with JQJT tablets, so
researchers and participants can not know the kind of
medication and group.
Twice unblinding method is adopted in this study.
Firstly, after close of data-base, the one who keep the
blind code will deliver a allocation schedule only signed
with group A and B to statistics department. Secondly,
after the handing of statistical outcome and final report,
the one keeping the blind code will declare real meaning
of group A and B. In case of emergency during this
trials, the blinding will be broken after obtaining the
consent of principle investigator.
Sample size
According to the results of the “JQJT tablets inter-
vene IGT study” by Professional Committee of Dia-
betes, Association of Integrative Medicine in Tianjin,
annual average tyoe 2 diabetes conversion rate of test
group is 4.05%, control group is 12.69%. The sample
was estimated according to the parameters: a = 0.05,
b =0 . 1
n
uu
Pe Pc

 
   


2
2 11 2 163 25 164
sin sin
.
Considering attrition of no more than 20%, the total
number of qualified cases in the groups will be 200 each
(n = 400).
Patient identification and enrollment
Diagnosis criteria (Guidelines for Clinical Diagnosis
and Treatment of Diabetes in 2008, ADA)
Impaired fasting glucose (IFG) (FPG5.6-6.9 mmol/L)
&/or impaired glucose tolerance (IGT) (FPG <5.6
mmol/L & OGTT 2 hPG 7.8-11.1 mmol/L)
TCM symptoms (Chinese New Medicine Treatment
of Diabetes Clinical Research Guiding Principle)
Dual deficiency of qi and yin or yin deficiency with
heat.
Inclusion criteria ￿ Fulfill pre-diabetes diagnostic
criteria;
￿ Fulfill TCM diagnostic criteria;
￿ Aged 18-75;
￿ Completed and submitted informed consent form;
Exclusion criteria ￿ History of diabetes (except gesta-
tional diabetes);
￿ Cardiovascular events(cerebrovascular accident in 6
months, history of myocardial infarction or heart
failure; severe organic heart disease; aneurysm with
the main artery or dissecting aneurysm; specific
angina, type II degree atrioventricular block, sick
sinus syndrome);
￿ Impaired hepatic and renal function: AST and/or
ALT 2- fold the upper limit of normal or above; same
for creatinine. Urine protein > ++ and/or hematuria.
￿ Fasting triglycerides ≥ 10 mmol/L;
￿ Endocrine disease, such as hyperthyroidism, autoal-
lergic disease, cancer or other serious fatal illness;
￿ Former use of glucocorticoid, b receptor blockers,
thiazide diuretics and nicotinic acid;
￿ Pregnancy, preparation of pregnancy and lactating
women;
￿ Suffering from mental diseases or non-cooperation
patients;
￿ Participating in other clinical trial within the last
two weeks;
￿ People refusing to provide consent for the study.
Rejection criteria ￿ Could not take medicine according
to the protocol.
￿ Data is incomplete.
Suspension criteria ￿ Poor compliance.
￿ Serious adverse events, complications and special
physiological changes.
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￿ Reluctance to continue this study.
￿ Taking medicine forbidding in this study.
￿ Withdraw for various reasons, such as failure to
follow up or death.
￿ Incomplete information which will influence the
study.
￿ Big mistake in protocol or significant deviation in
implement (such as the leak of blind).
￿ National laws, ministry of science and technology
or other authorities decided to terminate the study.
Follow up
Points of data capture (figure 1)
￿ Intervention period: 12 months; once a month for
12 months
￿ After intervention: the 2nd, 6th, 12th month after
intervention
Contents Data should be captured according table 1 and
2.
Outcome measures
Index of end point ￿ Occurrence of type 2 diabetes
(according to the guideline of ADA 2008);
￿ Blood glucose change to be normal.(FPG<5.6
mmol/L & OGTT 2 hPG <7.8 mmol/L)
Primary outcomes ￿ Oral glucose tolerance test
￿ Insulin releasing test
￿ Glycosylated hemoglobin (HA1c)
Secondary outcome measures ￿ Score of the Short
Form 36 Health Survey Questionnaire(SF-36)
￿ Scoring of TCM symptom (refer to clinical
research guidance of new Investigational drug in
TCM)
￿ Blood lipid: Total Cholesterol (TC), Triglyceride
(TG), High Density Lipoprotein-Cholesterol(HDL-
C), Low Density Lipoprotein-Cholesterol(LDL-C)
Safety index ￿ General medical examination
￿ Study visit blood and urine tests
￿ Functional examination: EKG, ALT, BUN, Cr
￿ Adverse events.
Measure and evaluate tools
Evaluation criteria of efficacy on diabetes conversion
rate (refer to the guideline of the diagnosis of diabetes
mellitus of ADA 2008)
Incidence of diabetes mellitus cases of diabetes mellitus  /
t total cases of each group100%
The rate of blood glucose return to normal (refer to
the guideline of the diagnosis of diabetes mellitus of
ADA 2008)
Reversion rate cases of blood glucose return to normal
eac
 /
h h group100%
The score of SF-36 Questionnaire is the evaluation of
various dimensions, entries, and between groups and
within group comparison of questionnaire total score.
The score is calculated with measurement data.
Evaluation of TCM symptom score (refer to clinical
research guidance of new Investigational drug in TCM)
Quantitative criteria of TCM symptom grades.
Adverse Event Monitoring
Report of adverse event When adverse event happens,
researchers must fill out the “SAE form” and report it to
Figure 1 Points of data capture(unit: month).
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The event should also be reported to the safety supervi-
sion division of the State Food and Drug Administration
within 24 hours.
Record of adverse event Adverse event report form
must be filled according to the real circumstances. Some
information, including occurrence time, severity, dura-
tion, adopted measure of the adverse event should be
noted as well.
Relationship between adverse event and investiga-
tional drugs Judgment of the relationship between the
administration time and adverse reactions; judgment of
the relationship between suspected and known adverse
reactions of investigational drug; whether suspected
adverse reactions disappear or mitigate after disconti-
nuation; whether the same reaction occurred again after
taking investigational drug once more.
Security evaluation criterion
￿ Safe without any adverse drug reaction.
￿ Relative safe with mild adverse drug reactions and
unnecessary treatment.
Table 1 Content of data capture(to be continued)
Item Screening period (unit: month) Intervention period (unit: month)
-0.5 1234567891 01 11 2
ICF X
Record of medical history X
Demographic information X
General physical examination X XXXXXXXXX X X X
F B G X XXXXXXXXX X X X
P B G X XXXXXXXXX X X X
OGTT X XXXXXXXXX X X X
Insulin release test X X
HbA1c X X
serum TC, LDL-C, VLDL-C X X
Blood and urine regulation X X X
ALT, AST X X X X X
BUN, Cr X X X X X
Electrocardiogram X
Pregnancy Test X X X
Selection/exclusion criteria X
Drugs of prohibition X
SF-36 X X
Evaluation of TCM Syndrome X X
Obtain random code X
Dial 800 to Assign drug X X X X
Drug Distribution and record X XXXXXXXXX X X
End-point events XXXXXXXXX X X X
Adverse events X XXXXXXXXX X X X
Drug combination XXXXXXXXX X X X
X: Item need to be done during different period.
Table 2 Content of data capture
Item Period after intervention (unit: month)
14 18 24
General physical examination X X X
FBG X X X
PBG X X X
OGTT X X X
Insulin release test X
HbA1c X
Serum TC, LDL-C, VLDL-C X
ECG X
Blood and urine regulation X
ALT, AST, BUN X
SF-36 X
Evaluation of TCM Syndrome X
Pregnancy test X X
End-point events X X X
Adverse events X X X
Drug combination X X X
X: Item need to be done during different period.
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necessary treatment.
￿ Stopping to take investigational drugs due to
adverse reactions.
Statistical Analysis Plan
Analysis parameters All parameters will be analyzed by
SAS 8.2 software package.
Analysis of data sets
￿ Full analysis set: According to the principle of ana-
lysis for intention to treat (ITT), participants will be
rejected by smallest and reasonable method. The last
observation carried forward (LOCF) method will be
used for the missing data supplement.
￿ Per-protocol set (PPS): PPS should be used in the
patients who satisfied with the following characters:
compliance is between 80% and 120%; not using
prohibited drugs; fit with inclusion criteria; case of
completed observation.
￿ Safety set (SS): All information of safety record will
be assessed, including adverse events and laboratory
test results.
￿ Statistical analysis method: Relative risk reduction
(RRR), absolute risk reduction (ARR), number
needed to treat (NNT) adopt nonparametric meth-
ods to evaluate the effectiveness. To adopt t-test,
repeated measure analysis of variance, radit test,
rank test, survival analysis, Cox proportional hazards
regression model and so on.
Mathematical statistics analysis and expression
￿ Comparison between groups: The chi-square test
for enumeration data; Wilcoxon rank sum test for
non-normal distribution of measurement data; t-test
for normal distribution of measurement data;
ANOVA for repeated measurement data; Ridit test
for ranked data; CMH test for the center effect.
￿ Dropping analysis: The chi-square test, or Fisher
exact probability method.
￿ Compliance analysis: The chi-square test, or Fisher
exact probability method.
Documents conservation and summary
The documents such as informed consent, signature of
participants and other cases are requested to conserve
clearly according to GCP by every unit after the study.
Researchers should preserve the material of clinical trial
for five years.
Data management
Data input Database manager designs EpiData3.1 data-
base. The data manager carries on the test to the data-
base base on analogue data or real CRF data. Data are
inputted by two full time personnel independently.
Data verification
￿ Comparing with duplicate input result.
￿ Checking data uniformity and logic.
￿ Spot-checking 10% CRF, compare database with
CRF form.
Data locked-up The main data will be locked up until
research completed. New question will carried on sta-
tistical analysis procedure after data locking; all con-
tents and the revision should be preserved well. For
the questions in the CRF, data manager should pro-
duce DQF and inquire the researchers through clinical
supervisor. Data manager should make data modifica-
tion, affirmation and record according to the reply of
researchers.
Management of investigational drug
JQJT tablets and placebo are all supplied by Longshun-
rong Pharmaceutical Company in Tianjin. According to
double-blind method, the packing of placebo should be
consistent with the investigational drug. Researchers will
be provided with the drug serial number and distribute
drugs to participants monthly through 800 telephone
terminals. The drug managers take charge of preserva-
tion of investigation agent. When adverse event hap-
pens, researchers can uncover blindness through the
DSMB.
Trial management
Change of protocol All changes of protocol should be
preserved and any modification of the protocol, includ-
ing ICF, must get the approval of ethics committee.
CRF tracking All signed ICF must be handed over even
if some of them are unqualified; any questions of CRF
or comments must be submitted directly to the
organizer.
Change of research center The decision to change
research center should be careful and these change
must be reported to ethics committee. Research center
would be changed for slow speed of study, severe viola-
tion of protocol and GCP.
Researcher’s responsibility
Researcher must understand protocol details and adhere
to it strictly. They should understand the related infor-
mation of investigation agent, including function, cura-
tive effect and security. They should have enough time
to complete this study on schedule and have responsibil-
ity to explain study process and consent form to partici-
pants. Participants with adverse events should be treated
suitably and related data should be recorded accurately
and completely in primitive medical record and CRF.
Researcher should accept censorship or examination
from organizer of clinical trial or other inspected
departments.
Quality control
Quality control of laboratory
￿ All hospitals should establish uniform SOP and
quality control sequence.
￿ All units should offer researcher suitable medical
equipments and emergency facilities.
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Request for researcher Researchers in this study must
possess the qualifications and ability to carry on it and
they should not be changed constantly.
Measures for compliance of participants Researchers
should give investigational drug to in-patient in time
and explain medication method to outpatient. Compli-
ance of participants will be inspected by method of drug
notation. They are asked to bring drug last time in
order to calculate the number.
compliance dispensing remaining dispensing   [( ) / ] % 100
Monitoring and inspection Monitor should constantly
visit each unit to know the situation of facility and
research follow, reexamine CRF, check storage of inves-
tigational drug and record of data.
According to GCP, organizer will carry on conven-
tional and emphasis inspection on related activities and
documents of every unit during study in order to evalu-
ate whether the process of study is in accord with pro-
tocol and standard practice, whether collected data are
recorded prompt, accurate and completely.
Bias control Any other west or TCM drugs which has
similar effects as the investigated agent will be prohib-
ited when participants decide to participate this study.
Researcher should pay close attention to contamination
and disturbance in this study in order to prevent occur-
rence of bias.
Ethics China clinical trial quality management norm/
Helsinki declaration
The study will guarantee to abide Chinese clinical trial
quality control standard and Helsinki manifesto.
Ethics committee
Before the beginning of study, all hospitals should pro-
vide related data about qualification of the main
researcher and laboratory conditions in order to help
ethics committee decide their participation. Each unit
needs not appraisal ethics again unless special request
and they can contract ethics committee and state rea-
sons if necessary.
Inform consent form
ICF must be reviewed and approved by ethics commit-
tees before study. Researchers should inform partici-
pants’ relevant information in words and writing
meanwhile by understandable language. ICF must be
signed by the participants or their representatives with
date. Before the signature of ICF, participants and repre-
sentatives should have adequate time to read it. Signed
ICF should be preserved properly by researchers and
participants independently.
Security
Researchers should keep related information of partici-
pants strictly in this study. Capital forms, numbers or
codes can be used to identification rather than names of
participants in CRF or other documents. Researchers
should preserve selected table which record code, name
and home address of participants.
Abbreviations
[JQJT]: Jin qi jiang tang; [CRF]: Case Report Form; [ICF]: Inform consent form;
[GCP]: Guild contribution point; [CRO]: Contract Research Organizations;
[RRR]: Relative risk reduction, [ARR]: Absolute risk reduction; [NNT]: Number
needed to treat; [SS]: Safety set; [PPS]: Per-protocol Set; [ITT]: Intention to
treat; [SAE]: Serious adverse event; [TC]: Total cholesterol; [HDL-C]: High
density lipoprotein cholesterol; [LDL-C]: low density lipoprotein cholesterol;
[TG]: Triglyceride; [ECG]: Electrocardiogralph; [OGTT]: Oral glucose tolerance
test; [HbA1c]: Hemoglobin A1c; [IR]: Insulin releasing; [ALT]: Alanine
transaminase; [AST]: Aspartate aminotransferase; [BUN]: Urea nitrogen; [Cr]:
Creatinine; [IFG]: Impaired fasting glucose; [IGT]: Impaired glucose tolerance;
[IVRS]: Interactive Voice Response System; [RCT]: Randomized controlled
clinical; [SF-36]: Short Form 36 Health Survey Questionnaire
Acknowledgements
The funding support of the National Basic Research Program of China (973
Program) is gratefully acknowledged. We especially wish to acknowledge
the help of the members of the Trial. We also acknowledge Dr. Jean-Jacques
Dugoua and Ms. Hou yazhu for their revision of this article.
Funding: The trial is sponsored by National Basic Research Program of
China (973 program; NO. 2009CB523003).
Author details
1Clinical Assessment Institute, Tianjin University of TCM, Yuquan street,
Tianjin, 300193, China.
2Baokang hospital, Tianjin university of TCM, Yuquan
street, Tanjin, 300193, China.
3Evidence Based Medicine Centre of Tianjin,
Anshanxidao street, Tianjin, 300193, China.
4Department of Integrated
Chinese and Western Medicine, The First Hospital of Peking University,
Xishiku Street, Xichen district, Beijing, 100034, China.
5Department of
Endocrinology, The Second Affiliated Hospital of Tianjin University of TCM,
Zhenli Street, Hebei District, Tianjin, 300150, China.
6Department of TCM,
Xijing hospital, Changlexilu Street, Xi’an, 710032, China.
7Department of
Endocrinology, The First Affiliated Hospital of Guangxi College of TCM,
Yuanhu Street, Nanning, 530023, China.
8Department of Endocrinology,
Metabolic Disease Hospital of Tianjin Medical University, Pingjiang Street,
Hexi District, Tianjin, 300211, China.
Authors’ contributions
HS, LG designed and finalised the protocol; HC, MR, YS were in charge of
the trial management. LX, BW were in charge of estimate of sample size and
statistics of result. JZ, HW, JH were in charge of monitoring. HS particularly
developed this publication describing the trial protocol and endpoint
assessment. WX, WD, CJ, LS, CL will assist with recruitment of participants. All
the authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 15 December 2009 Accepted: 10 March 2010
Published: 10 March 2010
References
1. Pan CY, Lu JM, Tian H, Kong XT, Lu XP, Yao C, Jiang CE, Deng XX, Wang SY,
Zhang XL, Wang ZS, Cui L: Study of the prevalence of diabetes mellitus
in adults in the shougang corporation in Beijing. Diabetes Med 1996,
13:663-68.
2. Pan Xiao Ren , LI Guang Wei , Hu Ying Hua , et al: Diet and exercise
intervention in the treatment of diabetes incidence rate of 530 cases of
impaired glucose tolerance 6 years prospective observation of the
crowd. Chinese Journal of internal medicine 1995, 34:108-111.
Cao et al. Trials 2010, 11:27
http://www.trialsjournal.com/content/11/1/27
Page 7 of 83. Xing Xiaoyan: The life style intervention treats IGT the feasibility and the
curative effect and the appraisal. Liaoning practical diabetes magazine
2003, 11:7-8.
4. Lu JM: Abnormal glucose metabolism with metabolic syndrome risk
investigation and analysis - discussion suited to the Chinese population
with metabolic syndrome diagnostic criteria. Chinese Journal of Diabetes
2004, 12:340-343.
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-
NIDDM Trial Research Group: Acarbose treatment and the risk of
cardiovascular disease and hypertension in patients with impaired
glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-94.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,
Walker EA, Nathan DM, Diabetes Prevention Program Research Group:
Diabetes prevention program research group reduction in the incidence
of type 2 diabetes with lifestyle intervention metformin. N Engl J Med
2002, 346:393-403.
7. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA: TRIPOD
(TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-
controlled trial of troglitazone in women with prior gestational diabetes
mellitus. Controlled Clinical Trials 1998, 19:217-31.
8. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone
Medication) trial investigators: Effect of rosiglitazone on the frequency of
diabetes in patients with impaired glucose tolerance or impaired fasting
glucose: a randomized controlled trial. Lancet 2006, 368:1096-105.
9. The DREAM trial investigators: Effect of ramipril on the incidence of
diabetes. N Engl J Med 2006, 355:1551-62.
10. Chan KL: On the treatment of diabetes in Chinese medicine research
and development. Foreign Medical endocrinology fascicle 2004, 24:150.
11. Yan KL: Astronavigation, and so on. Beijing Chinese medicine university
masters graduation thesis 2007.
12. Zhou ZN: Jinqi Jiangtang tablet on impaired glucose tolerance to
explore the efficacy. Practical Journal of Investigational drug 2002, 18:3-4.
13. Shen ZF, Xie MZ, Liu HF: Influence of JinQI-jiangtang tablet on animals of
glycometabolism. Traditional Chinese Drug Research & Clinical Pharmacology
1996, 7(2):24-26.
14. Mechanism of Chinese goldthread on reduction of blood sugar.
Shandong Journal of Traditional Chinese Medicine 2005, 11:688.
15. Ji LL: The herbalism analysis of berberine on diabetes. J Sichuan Tradit
Med 1999, 11:17-19.
16. Xie MZ, Liu HF: Influence of JiQi-Jiangtang on blood fat, insulin
resistance, immune function of animals. Traditional Chinese Drug Research
& Clinical Pharmacology 1997, 1:23-24.
17. Shen ZF: Pharmacological base of JinQi-Jiangtang tablet on diabetes.
Foreign Medical Sciences Section of Endocrine 2004, 24:215-216.
18. Gu WY: Clinical evaluation of efficacy of Jinqi hypoglycemic tablet with
Gliclazide in the treatment of type 2 diabetes mellitus. Journal of Tianjin
Medical University 2004, 1:87-89.
19. Zhang RR, Liu Y: The influence of JinQi-Jiangtang tablet on excretion rate
of microalbumin of IGT patients. Tianjing Medical Journal 2005, 33:301-30.
doi:10.1186/1745-6215-11-27
Cite this article as: Cao et al.: JinQi-Jiangtang tablet, a Chinese patent
medicine, for pre-diabetes: a randomized controlled trial. Trials 2010
11:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cao et al. Trials 2010, 11:27
http://www.trialsjournal.com/content/11/1/27
Page 8 of 8